189 related articles for article (PubMed ID: 30853214)
21. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
22. SIRT2 deletion enhances KRAS-induced tumorigenesis in vivo by regulating K147 acetylation status.
Song HY; Biancucci M; Kang HJ; O'Callaghan C; Park SH; Principe DR; Jiang H; Yan Y; Satchell KF; Raparia K; Gius D; Vassilopoulos A
Oncotarget; 2016 Dec; 7(49):80336-80349. PubMed ID: 27637077
[TBL] [Abstract][Full Text] [Related]
23. In vivo reprogramming drives Kras-induced cancer development.
Shibata H; Komura S; Yamada Y; Sankoda N; Tanaka A; Ukai T; Kabata M; Sakurai S; Kuze B; Woltjen K; Haga H; Ito Y; Kawaguchi Y; Yamamoto T; Yamada Y
Nat Commun; 2018 May; 9(1):2081. PubMed ID: 29802314
[TBL] [Abstract][Full Text] [Related]
24. Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma.
Liu YH; Hu CM; Hsu YS; Lee WH
Cell Death Dis; 2022 Sep; 13(9):817. PubMed ID: 36151074
[TBL] [Abstract][Full Text] [Related]
25. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
[TBL] [Abstract][Full Text] [Related]
26. Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras.
Gidekel Friedlander SY; Chu GC; Snyder EL; Girnius N; Dibelius G; Crowley D; Vasile E; DePinho RA; Jacks T
Cancer Cell; 2009 Nov; 16(5):379-89. PubMed ID: 19878870
[TBL] [Abstract][Full Text] [Related]
27. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer.
Yao W; Rose JL; Wang W; Seth S; Jiang H; Taguchi A; Liu J; Yan L; Kapoor A; Hou P; Chen Z; Wang Q; Nezi L; Xu Z; Yao J; Hu B; Pettazzoni PF; Ho IL; Feng N; Ramamoorthy V; Jiang S; Deng P; Ma GJ; Den P; Tan Z; Zhang SX; Wang H; Wang YA; Deem AK; Fleming JB; Carugo A; Heffernan TP; Maitra A; Viale A; Ying H; Hanash S; DePinho RA; Draetta GF
Nature; 2019 Apr; 568(7752):410-414. PubMed ID: 30918400
[TBL] [Abstract][Full Text] [Related]
28. Activation-Induced Cytidine Deaminase Contributes to Pancreatic Tumorigenesis by Inducing Tumor-Related Gene Mutations.
Sawai Y; Kodama Y; Shimizu T; Ota Y; Maruno T; Eso Y; Kurita A; Shiokawa M; Tsuji Y; Uza N; Matsumoto Y; Masui T; Uemoto S; Marusawa H; Chiba T
Cancer Res; 2015 Aug; 75(16):3292-301. PubMed ID: 26113087
[TBL] [Abstract][Full Text] [Related]
29. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis.
Santana-Codina N; Roeth AA; Zhang Y; Yang A; Mashadova O; Asara JM; Wang X; Bronson RT; Lyssiotis CA; Ying H; Kimmelman AC
Nat Commun; 2018 Nov; 9(1):4945. PubMed ID: 30470748
[TBL] [Abstract][Full Text] [Related]
30. Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated With Smaller Lesions.
Nagawkar SS; Abu-Funni S; Simon E; Bick T; Prinz E; Sabo E; Ben-Izhak O; Hershkovitz D
Pancreas; 2016 Jul; 45(6):876-81. PubMed ID: 26646269
[TBL] [Abstract][Full Text] [Related]
31. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
[TBL] [Abstract][Full Text] [Related]
32. Zeb1 in Stromal Myofibroblasts Promotes
Sangrador I; Molero X; Campbell F; Franch-Expósito S; Rovira-Rigau M; Samper E; Domínguez-Fraile M; Fillat C; Castells A; Vaquero EC
Cancer Res; 2018 May; 78(10):2624-2637. PubMed ID: 29490942
[TBL] [Abstract][Full Text] [Related]
33. KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas.
Krasinskas AM; Moser AJ; Saka B; Adsay NV; Chiosea SI
Mod Pathol; 2013 Oct; 26(10):1346-54. PubMed ID: 23599154
[TBL] [Abstract][Full Text] [Related]
34. Bmi1 combines with oncogenic KRAS to induce malignant transformation of human pancreatic duct cells in vitro.
Chen SJ; Chen YT; Zeng LJ; Zhang QB; Lian GD; Li JJ; Yang KG; Huang CM; Li YQ; Chu ZH; Huang KH
Tumour Biol; 2016 Aug; 37(8):11299-309. PubMed ID: 26951514
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of HER2 in the pancreas promotes development of intraductal papillary mucinous neoplasms in mice.
Shibata W; Kinoshita H; Hikiba Y; Sato T; Ishii Y; Sue S; Sugimori M; Suzuki N; Sakitani K; Ijichi H; Mori R; Endo I; Maeda S
Sci Rep; 2018 Apr; 8(1):6150. PubMed ID: 29670173
[TBL] [Abstract][Full Text] [Related]
36. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.
Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X
Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia.
Pylayeva-Gupta Y; Lee KE; Hajdu CH; Miller G; Bar-Sagi D
Cancer Cell; 2012 Jun; 21(6):836-47. PubMed ID: 22698407
[TBL] [Abstract][Full Text] [Related]
38. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma.
Liang C; Qin Y; Zhang B; Ji S; Shi S; Xu W; Liu J; Xiang J; Liang D; Hu Q; Ni Q; Xu J; Yu X
Mol Cancer Res; 2017 Feb; 15(2):201-212. PubMed ID: 28108627
[TBL] [Abstract][Full Text] [Related]
39. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein.
Dai E; Han L; Liu J; Xie Y; Kroemer G; Klionsky DJ; Zeh HJ; Kang R; Wang J; Tang D
Autophagy; 2020 Nov; 16(11):2069-2083. PubMed ID: 31920150
[No Abstract] [Full Text] [Related]
40. SWI/SNF component
Wang SC; Nassour I; Xiao S; Zhang S; Luo X; Lee J; Li L; Sun X; Nguyen LH; Chuang JC; Peng L; Daigle S; Shen J; Zhu H
Gut; 2019 Jul; 68(7):1259-1270. PubMed ID: 30315093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
